• Sudhir Datar and Alejandro A Rabinstein.
• aDepartment of Neurology and Anesthesiology, Wake Forest University School of Medicine, Winston Salem, North Carolina bDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
• Curr Opin Crit Care. 2017 Apr 1; 23 (2): 87-93.

Purpose Of ReviewSubarachnoid hemorrhage from a ruptured aneurysm (aSAH) is a complex disorder with the potential to have devastating effects on the brain as well as other organ systems. After more than 3 decades of research, the underlying pathophysiologic mechanisms remain incompletely understood and important questions remain regarding the evaluation and management of these patients. The purpose of this review is to analyze the recent literature and improve our understanding of certain key clinical aspects.Recent FindingsGrowing body of evidence highlights the usefulness of CT perfusion scans in the diagnosis of vasospasm and delayed cerebral ischemia (DCI). Hypervolemia leads to worse cardiopulmonary outcomes and does not improve DCI. The traditional triple H therapy is falling out of favor with hemodynamic augmentation alone now considered the mainstay of medical management. Randomized controlled trials have shown that simvastatin and intravenous magnesium do not prevent DCI or improve functional outcomes after aneurysmal subarachnoid hemorrhage (aSAH). Emerging data using multimodality monitoring has further advanced our understanding of the pathophysiology of DCI in poor grade aSAH.SummaryThe brief review will focus on the postinterventional care of aSAH patients outlining the recent advances over the past few years.

15 keywords...

hide…